We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Actavis Buys Alpharma's Generics Business for $810 Million
Actavis Buys Alpharma's Generics Business for $810 Million
October 17, 2005
Iceland-based drugmaker Actavis has taken another major step to expand its presence in the generics market, announcing Oct. 17 that it plans to purchase Alpharma’s U.S. and international generics businesses for roughly $810 million.